Celgene (NASDAQ:CELG) Likely to Post Impressive Third Quarter Results Today

Today Celgene (NASDAQ:CELG) will announce its results for the third quarter, which promise to be healthy. The main reason for this optimism is the company’s primary drug Revlimid, which had strong sales in its third quarter this year. Revlimid’s per quarter sales are recorded at $1 billion, which makes up for two-third of the company’s total revenue.

Even though it’s the best source of revenue, but Revlimid is not the only drug Celgene (NASDAQ:CELG) has in its arsenal. The company has a line-up of a few new drugs that promise to add to its overall revenue; therefore Celgene (NASDAQ:CELG) for the time being should be on every investor’s watch-list.

Celgene (NASDAQ:CELG)’s Abraxane is likely to record sales between $850 and $900 million – a figure that is extremely high. Abraxane’s sales for the second quarter were up by 39% on a year-over-year basis the main reason for which was its approval in Europe’s and US’ pancreatic cancer category.

This year’s first half for Celgene (NASDAQ:CELG) brought sales of $400 million and to reach its low-end milestones the company needs another round of $450 million sales in the year’s second half.

Celgene (NASDAQ: CELG)’s drug for multiple myeloma, Pomalyst got its approval in the year 2013, which is also likely to feature in the company’s third quarter results. Its year-over-year sales went up by 143%; this figure includes only its US sales in the first quarter; the drug was later approved in Europe as well; therefore it is likely to post some healthy sales figures. If all goes well for Pomalyst and it can boost its sales a bit then its sales may hit the $700 million mark by the end of this year.

Celgene (NASDAQ:CELG)’s Otezla was launched this year in April and may not be a strong contributor to the overall revenue of the company yet; it may be the one to watch in the company’s next quarter. Otezla has its FDA psoriatic arthritis and Plaque psoriasis treatment approval. The report may show its sales progress so far; considering the fact that it only had a month in the third quarter, nothing major should be expected from it. However the drug looks promising because unlike its competitors in the market, it can be taken orally whereas others have to be injected.

The drug will take a few years to become a great source of revenue for the company. But it may be difficult for the drug to find its patients among the ones that are already using its competitors; therefore it will have to rely on finding new patients who do not want to rely on injections for treatment. Otezla was one of the market leaders in its second quarter in the category of new psoriatic arthritis’ new patients, which shows its potential.

Celgene (NASDAQ:CELG) is hoping to manufacture treatments for a few other inflammation diseases as well, which include Behcet’s disease, ulcerative colitis and rheumatoid arthritis.

Celgene (NASDAQ:CELG) 52-week high is the best ever for the company and its stock is currently trading closer to this value. The main reason is GED-0301’s sales.